期刊文献+

利用基因表达谱芯片筛选卵巢癌相关差异表达基因的研究 被引量:1

下载PDF
导出
摘要 目的:探讨VEGF、HE4、YKL-40、OPN、BRCA1基因在卵巢癌发生发展中的作用。方法:采用cDNA芯片技术分别检测13例卵巢癌和5例正常卵巢组织中上述基因cDNA表达谱差异。结果:VEGF、HE4、YKL-40、OPN基因在卵巢癌组织中表达上调;BRCA1基因在卵巢癌组织中表达下调。结论:上述基因与卵巢癌发生及发展关系密切。CDNA基因芯片技术对于探讨卵巢癌分子机制,寻找卵巢癌分子标志物具有重要意义。
出处 《中国社区医师(医学专业)》 2011年第17期204-204,206,共2页
  • 相关文献

参考文献11

  • 1张向宁,李晓翠,韩秋峪,张华伟,徐明彩.卵巢癌患者血清MMP-9、VEGF的变化及意义[J].山东医药,2004,44(24):6-7. 被引量:4
  • 2Vincenti V,Cassano C,Rocchi M,Persico G.Assignment of the vascularend othelial growth factor gene to human chromosome 6p21.3.Circulation,1996,15(93):1493-1495.
  • 3Wei MH,Popescu NC,Lerman MI,et al.Zimonjic DB.Localization of the human vascular endothelial growth factor gene,VEGF,at chromosome 6p12[J].Hum Genet,1996,9:7794-7975.
  • 4Vu TH,Shipley JM,Bergers G,et al.Gelatinases is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes[J].Cell,1998,93(3):411-422.
  • 5Moore R,Brown A,Miller M,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,108:402-408.
  • 6Moore R,McMeekin D S,Brown AK,et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the predicti on of ovarian cancer in patients with a pelvic mass[J].Gynecol Oncol,2009,112:40-46.
  • 7王术艺,谢永红,张杰,张红娟,李涛,李军良,金海红,张丽娜,赵淑艳.HE4和CA125联合检测在卵巢癌手术前后临床价值评价[J].河北医药,2009,31(5):564-565. 被引量:37
  • 8Zhang J,Takahashi K,Takahashi F,et al.Differential osteopontin expression in lung cancer[J].Cancer Lett,2001,171(2):215.
  • 9管桂峰.OPN及HE4基因在上皮性卵巢癌中的表达及临床意义[J].医药论坛杂志,2009,30(10):9-10. 被引量:16
  • 10Christopher P.Lessons from BRCA:The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer.Clin Med Res,2007,5(1):35-44.

二级参考文献26

  • 1马小玲,张玉泉.骨桥蛋白与卵巢上皮性癌关系的研究进展[J].中华妇产科杂志,2006,41(7):495-497. 被引量:6
  • 2杨静华,刘建辉,孙志平.卵巢癌患者血清骨桥蛋白和CA125的检测及临床意义[J].中国计划生育学杂志,2007,15(5):303-305. 被引量:6
  • 3De Nitolis M,Garbisn S,Lueanrini G,et al. 72-kilodalton type Ⅳ collagenase,type Ⅳ collagen,and ki67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol, 1996,15:102 ~ 109.
  • 4Grew JP ,Brient O,Bicknell R,et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol, 1999,161 : 799~ 803.
  • 5Jocobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol,2000,163:343~348.
  • 6Palay PJ,Staskas KA,Ochs A, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer, 1997,80:98~106.
  • 7Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 1999,85 : 178 ~ 187.
  • 8Riedel F, Gottek, Schwalb J, et al. Expression of 92-kDa Ⅳcollagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol, 2000,7:1099~1105.
  • 9Zucker S, Mria H,Conner CE, et al. Vascular endothelial growth factor induce tissue factor and matrix metalloproteinase production in endothelial cells : conversion of prothrombin results in progelatinase an activation and cell proliferation. Int J Cancer, 1998, 75:780~786.
  • 10Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol, 1999,73:56-61.

共引文献50

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部